Your browser doesn't support javascript.
loading
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
Howard, James F; Vissing, John; Gilhus, Nils E; Leite, M Isabel; Utsugisawa, Kimiaki; Duda, Petra W; Farzaneh-Far, Ramin; Murai, Hiroyuki; Wiendl, Heinz.
Affiliation
  • Howard JF; Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Vissing J; Department of Clinical Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Gilhus NE; Department of Clinical Medicine, University of Bergen and Haukeland University Hospital, Bergen, Norway.
  • Leite MI; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Utsugisawa K; Department of Neurology, Hanamaki General Hospital, Hanamaki, Iwate, Japan.
  • Duda PW; UCB Pharma, Cambridge, MA, USA.
  • Farzaneh-Far R; UCB Pharma, Cambridge, MA, USA.
  • Murai H; Department of Neurology, International University of Health and Welfare, Narita, Chiba, Japan.
  • Wiendl H; Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.
Expert Opin Investig Drugs ; 30(5): 483-493, 2021 May.
Article in En | MEDLINE | ID: mdl-33792453
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement Inactivating Agents / Myasthenia Gravis Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2021 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement Inactivating Agents / Myasthenia Gravis Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2021 Document type: Article Affiliation country: